Pseudouridine is a modified nucleoside derived from RNA catabolism; the concentration of this nucleoside is elevated in body fluids of both tumour-bearing and human immunodeficiency virus (HIV) infected patients. We used an HPLC procedure to evaluate the serum pseudouridine concentration in patients with chronic hepatitis C in an attempt to determine whether the nucleoside serum concentration was related to the response to a-interferon treatment.
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Interferons are a heterogeneous family of glycoprotems /1, granulocyte count < 1.5 X 10 9 /1. The study protocols were approved by the local ethics committee and informed consent to the study was obtained from each patient.
Sample collection
Venous blood was collected into vacutainers tube (Becton Dickinson, Milan, Italy) and centrifuged within 2 h of withdrawal; alanine and aspartate aminotransferase were analysed thereafter. Aliquots of serum samples were stored at -80 °C until pseudouridine analysis. Alanine and aspartate aminotransferase were assayed with a Cobas Mira S analyser (Roche Diagnostic Systems, Milan, Italy) using reagents from Roche.
Hepatitis C virus RNA detection
The serum of those patients positive for anti-hepatitis C virus antibody by second generation enzyme-linked immunosorbent assay (ELISA Ortho Diagnostic, Milan, Italy), was then tested for hepatitis C virus-RNA, using Amplicore HCV (Roche Diagnostic Systems, Milan, Italy).
Treatment with a-interferon
Twenty-one patients (10 males and 11 females) with active chronic hepatitis C, showing an increase of alanine aminotransferase of at least twice the upper limit of the reference range for more than 6 months, received 3 MU of recombinant interferon a-2b (Intron A) subcutaneously three times a week for 3 months. Patients who responded to treatment, i. e., return to normal serum alanine aminotransferase levels, received 3 MU of α-interferon for another 9 months and then 2 MU for 2 months and 1 MU for 1 month. Nonresponder subjects, after the first three months of treatment, were given a second cycle of α-interferon at 6 MU for 6 months; if their serum alanine aminotransferase levels normalized, they underwent a protocol with decreasing doses. Therapy was stopped in nonresponder subjects. Pseudouridine serum concentrations were measured at 1, 3, 6 and 12 months from the beginning of interferon therapy.
Pseudouridine determination
Serum pseudouridine was measured as previously described (17) . Briefly, 0.5 ml of serum was deproteinized with an equal volume of cold acetonitrile, kept on ice for 15 min and centrifuged at 3000 g for 10 min. Nucleosides were purified by affinity chromatography on phenylboronic gel (Affigel 601, Bio Rad Laboratories, Segrate, Italy) equilibrated with 0.25 mol/1 ammonium acetate, pH 8.5. Nucleosides were eluted with 15 ml of 0.1 mol/1 formic acid; 2.5 nmol/250 μΐ of 2'-deoxyguanosine were added as internal standard, after which the samples were lyophilized. Aliquots of 25 μΐ were injected onto a C 18^B ondapack column (Waters Associates, USA) in an HPLC HP 1050 system (Hewlett Packard, USA). The column was eluted with 10 mmol/1 NH4H 2 P0 4 solution containing 60 ml of CH 3 OH per litre at a flow-rate of 1 ml/min. Pseudouridine peaks were recorded and integrated with a 3396 HP system. All the reagents were of HPLC grade.
Statistics
The means and standard deviations were computed for each variable. The ANOVA "one-way" analysis of the variance (Epistat program) was used to evaluate significance.
Results
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In the 26 controls the serum concentrations of pseudouridine, aspartate aminotransferase and alanine aminotransferase were 2.6 ± 0.2 mmol/1, 25 ± 13 U/l and 23 ± 16 U/l, respectively. This was in good agreement with the reference range of pseudouridine previously found in a healthy population from Italy and the United States (18) . The pseudouridine cut-off level was set at the mean value plus 2 S.D. of normal controls (3.0 μιηοΐ/ΐ).
The pseudouridine serum concentrations determined in the 38 patients with chronic hepatitis C at diagnosis and before any treatment are shown in table 1. Serum pseudouridine was higher in 29 (76%) of these 38 patients than in the control group, and serum aminotransferase levels were in the reference range.
Of the 21 patients treated with α-interferon, 12 responded to treatment and 9 did not. Table 2 shows the mean values of pseudouridine, alanine and aspartate aminotransferase in the 12 responders and in the 9 nonresponders. In the 12 responder patients normalization of aminotransferase paralleled the decrease in pseudouridine concentration to the reference range. In contrast, pseudouridine concentration increased significantly in non-responder patients. The highest serum pseudouridine concentrations were found in the 6 patients with chronic C hepatitis which had evolved to liver cirrhosis. creased gradually during treatment, although the greatest decrease occurred in the first month of α-interferon therapy. It is noteworthy that pseudouridine concentration preceded the normalization of alanine aminotransferase, in fact the pseudouridine concentrations had already decreased to reference values after the first month of treatment, while alanine aminotransferase was stationary.
Discussion
Interferon is currently becoming the treatment of choice in chronic hepatitis C virus infection. However, the response to interferon treatment is heterogeneous, and is probably related to viral strain, genetic factors or host immunity (19, 20) . Moreover, there is as yet no laboratory test giving an early prediction of the success or otherwise of interferon therapy. Currently, the response to treatment is evaluated from the normalization of serum alanine aminotransferase and the loss of virus from the serum as detected by quantitative polymerase chain reaction (PCR) of hepatitis C virus-RNA. However, PCR is still far from being a routine test, because of the lack of standardization, risk of contamination and poor automation. Other markers, such as the Knodell index, procollagen III and anti-hepatitis C virus antibodies, are under study and may serve as adjunctive markers of treatment response (21, 22) .
We examined the relationship between pseudouridine serum concentration and the response to a-interferon treatment in patients with chronic hepatitis C to assess the possibility of using pseudouridine, a catabolic RNA index, as a biochemical marker of the replicative blockage of the viral cycle induced by interferon. We determined the serum pseudouridine concentration in patients with chronic hepatitis C at initial diagnosis and before any therapeutic treatment, to evaluate the correlation of the elevation of the nucleoside with the disease activity. Pseudouridine levels were significantly elevated in 76% of the patients, and even higher levels were found in six patients with liver cirrhosis. The elevation of the nucleoside in the 6 cirrhotics agrees with a study in which the pseudouridine concentration increased when cirrhosis evolved to hepatocellular carcinoma (23) . Possibly these patients with advanced disease are in transition phase to hepatocellular carcinoma, or they could already have developed an undetectable small cancer.
A significant decrease in pseudouridine serum levels occurred only in cases of an effective response to a-interferon treatment (responder patients), thus revealing a good correlation between the response to the therapy and the nucleoside serum concentration. Long-term (12 months) therapy monitoring showed that the pseudouridine serum concentration decreased soon after the beginning of α-interferon therapy and much earlier than alanine aminotransferase normalization.
Elevated excretion of pseudouridine has been demonstrated in patients with various malignancies (8) (9) (10) (11) (12) (13) (14) (15) (16) , although the biochemical basis of this phenomenon is unclear. That the increase in pseudouridine level is diseaserelated and not caused by tissue destruction is supported by the observation that in cancer patients the elevated excretion of pseudouridine and other modified nucleosides is the consequence of a higher turnover rate of tRNA in tumour tissue than in the corresponding normal tissue (24) . It is not unreasonable to suppose that the excretion of pseudouridine in patients infected by hepa- a from the beginning of α-interferon treatment titis C virus is increased. In fact, although the mechanisms of intracellular hepatitis C virus replication have not yet been clarified, it seems conceivable that, since hepatitis C virus is a positive-stranded RNA virus, early molecular events of the virus cycle such as the translation of the viral proteins, are accompanied by an enhanced turnover-rate of the RNA populations involved. Furthermore, the activity of enzymes involved in nucleoside metabolism appears to be increased in cirrhotic subjects (25) and HIV patients excrete elevated levels of pseudouridine (8, 16) . Lastly, the structure of the genomic HCV region encoding the E 2 envelope protein is similar to that of HIV gp!20 envelope protein (26).
In conclusion, given the correlation between serum pseudouridine levels and the effective responses to ainterferon treatment of patients with chronic hepatitis C, and given the simplicity and accuracy of the methodology, serum pseudouridine might be clinically useful as a marker of the response to interferon treatment in chronic hepatitis C. However, a more extended investigation on a greater number of patients is needed to verify this hypothesis and to evaluate the possible predictive value of pseudouridine for the response to c^interferon treatment.
